Navodiš nešto što je dostupno samo nakon registracije, a teoretski je registracija moguća samo zdravstvenim djelatnicima, a ne i laicima. Laici ne vide ovo što si naveo.mujica prvotno napisa
Gle, velika je razlika između ovoga, navedenog pod broj jedan u rubrici nuspojave:
"Hepatotoxicity
Cases of liver failure, some leading to liver transplant or death, have occurred with the use of Lamisil Tablets in individuals with and without pre-existing liver disease.
In the majority of liver cases reported in association with Lamisil use, the patients had serious underlying systemic conditions. The severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease. Treatment with Lamisil Tablets should be discontinued if biochemical or clinical evidence of liver injury develops.
Lamisil Tablets are not recommended for patients with chronic or active liver disease. Before prescribing Lamisil Tablets, pre-existing liver disease should be assessed. Hepatotoxicity may occur in patients with and without pre-existing liver disease. Patients prescribed Lamisil Tablets should be warned to report immediately to their physician any symptoms of persistent nausea, anorexia, fatigue, vomiting, right upper abdominal pain or jaundice, dark urine or pale stools. Patients with these symptoms should discontinue taking oral terbinafine, and the patient’s liver function should be immediately evaluated."
I ovoga, dostupnog na halmed bez registracije, odnosno dostupnog laicima (u pdf-u je, a i bolje je da ne kopiram sve na forum):
http://www.halmed.hr/upl/lijekovi/PI...-06-02-209.pdf
gdje se hepatotoksičnost maltene sporadično spominje te ovoga,
dostupnog samo registriranim korisnicima:
http://www.almp.hr/upl/lijekovi/SPC/...-06-02-209.pdf
a čak i to dosta je različito od onog američkog linka...
Toliko o pravu na informiranost....
Ovo je samo nekaj na što sam slučajno naletila jer me netko tražio da mu to nabavim...pa me šokirala različitost informacija na dva izvora...
 |
|||
